Veradermics, (MANE)
The price, the headline numbers and the latest news, in one place.
Veradermics, (MANE) Stock Price, Analysis & Data
| Bid | 95.6 |
| Market Cap | 4.12B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -104M |
| 0.00 | |
| -2.49 | |
| n/a | |
| -36.66 | |
| P/B (ttm) | 5.06 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 12, 2026 |
| Ask | 110 |
| Volume | 362,791 |
| Avg. Volume (20D) | 717,338 |
| Open | 98.92 |
| Previous Close | 97.75 |
| Day's Range | 97.20 - 99.84 |
| 52-Week Range | 32.00 - 131.24 |
| Analyst | n/a |
| Price Target | 167 (69.53%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray pa...
Financial Performance
In 2025, Veradermics,'s revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -70M, an increase of 164.25%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for MANE stock is "null". The 12-month stock price forecast is 167, which is upside of 69.53% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.58 exceeds estimates by 0.06, with -Infinity% YoY decline.
Analysts project revenue of ... Upgrade
